Abstract
500 patients with hepatitis B have been followed up from the acute onset to long-term outcome. As for chronic transformation of the disease, at higher risk are patients with mild form, progredient run and inadequate immune response. Of the highest value for identification and prognostication was a dynamic quantitative control over the system HBeAg-anti-HBe providing separate prognosis of establishment of replicative or integrative variants of chronic hepatitis B. In progredient infection an early administration of reaferon in combination with thymogen is thought valid which in many patients is sufficient to prevent the disease transformation into a chronic form.
MeSH terms
-
Acute Disease
-
Adjuvants, Immunologic / therapeutic use
-
Adult
-
Algorithms
-
Biomarkers / blood
-
Dipeptides*
-
Disease Progression
-
Drug Therapy, Combination
-
Hepatitis B / immunology*
-
Hepatitis B / therapy
-
Hepatitis B Antibodies / blood
-
Hepatitis B Antigens / blood
-
Hepatitis, Chronic / immunology*
-
Hepatitis, Chronic / prevention & control
-
Humans
-
Interferon Type I / therapeutic use
-
Interferon alpha-2
-
Interferon-alpha
-
Peptides / therapeutic use
-
Prognosis
-
Recombinant Proteins
-
Risk Factors
Substances
-
Adjuvants, Immunologic
-
Biomarkers
-
Dipeptides
-
Hepatitis B Antibodies
-
Hepatitis B Antigens
-
Interferon Type I
-
Interferon alpha-2
-
Interferon-alpha
-
Peptides
-
Recombinant Proteins
-
thymogen